Abstract:Background: Children with HIV are at increased risk of acquiring tuberculosis (TB), a common cause of acute and chronic respiratory disease and death in HIV-infected children living in areas where prevalence of the disease is high. Children infected with HIV and TB have worse outcomes than HIV-uninfected children who have TB; thus, preventing the infection and disease in HIV-infected children is potentially an important public health intervention. Isoniazid, an anti-tuberculosis medication, has been used effectively to prevent TB in HIV-uninfected children, but currently there are no guidelines on the use of TB preventive therapy in HIV-infected children. Objectives: To determine the impact of TB preventive therapy on TB-related incidence and death in HIV-infected children Search strategy: We searched the Cochrane Controlled Trials Register (CENTRAL/CCTR), Cochrane HIV/AIDS Group Specialized Register, MEDLINE/PubMed, EMBASE, and AIDSearch. In addition, we scanned reference lists, manually searched conference abstracts, and contacted content experts. Selection criteria: We included studies of HIV-infected children randomised to receive TB preventive therapy or placebo, or an alternative TB preventive regimen. Participants could have tuberculin skin test results that were positive or negative. Data collection and analysis: Two authors independently used the study selection criteria, assessed methodological quality and extracted data. Effects were assessed using hazard ratios. Main results: One trial met the selection criteria for the review. The trial participants were HIV-infected children, most of whom were not taking antiretroviral therapy. Subjects were randomised to isoniazid and cotrimoxazole or placebo and cotrimoxazole, given daily or three times a week. The trial showed a marked reduction in TB incidence and death in the isoniazid group. As yet, however, there are no long-term follow-up data on the durability of the protective effect or on possible long-term adverse events. This trial also was unable to assess the impact of isoniazid prophylaxis on children receiving antiretroviral therapy. Authors' conclusions: Isoniazid prophylaxis in HIV-infected children has the potential to play a major public health role by reducing TB incidence and death. As yet, however, data are insufficient to guide the duration of prophylaxis and to support its use in children using highly active antiretroviral therapy (HAART) and in those living in areas of low TB prevalence. Further studies are needed to assess whether TB preventive therapy is of benefit in all HIV-infected children, irrespective of use of antiretroviral treatment, the optimal duration of preventive therapy, or long-term adverse events.

Immunopathogenesis in HIV-associated pediatric tuberculosis

Pediatric immunotherapy and HIV control

HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment

Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children

The immunology of tuberculosis: from bench to bedside.

Advances in Antiretroviral Therapy for Patients with Human Immunodeficiency Virus-Associated Tuberculosis

Host Immunity to Mycobacterium tuberculosis Infection Is Similar in Simian Immunodeficiency Virus (SIV)-Infected, Antiretroviral Therapy-Treated and SIV-Naïve Juvenile Macaques

Impact of in-utero exposure to HIV and latent TB on infant humoral responses

Pulmonary disease in HIV-infected African children

Mycobacterium tuberculosis-Human Immunodeficiency Virus Infection and the Role of T Cells in Protection

Progress in immunology of tuberculosis and new vaccine development

A gut check: understanding the interplay of the gastrointestinal microbiome and the developing immune system towards the goal of pediatric HIV remission

infection associated immune perturbations correlate with antiretroviral immunity

Tuberculosis: Current state of knowledge: An Epilogue

Advances in Understanding Immune Homeostasis in Latent Tuberculosis Infection.

Study on Mycobacterium tuberculosis-specific cellular immunity in individuals co-infected with Mycobacterium tuberculosis and human immunodeficiency virus

Tuberculosis and HIV Coinfection–the Challenge in the Prevention, Detection and Treatment of Tuberculosis

Incidence of active tuberculosis in HIV-infected individuals not receiving universal tuberculosis preventive treatment

Mortality of children and adolescents co-infected with tuberculosis and HIV: a systematic review and meta-analysis

HIV infection impairs the host response to Mycobacterium tuberculosis infection by altering surfactant protein D function in the human lung alveolar mucosa

Immunological effects of the PE/PPE family proteins of Mycobacterium tuberculosis and related vaccines